Ⅲ-Ⅳa期鼻咽癌LMP特异性T细胞免疫反应与临床分析

doi:10.3760/cma.j.cn113030-20220228-00079

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To explore the Epstein-Barr virus (EBV) latent infection membrane protein (LMP) 1 or LMP2 specific T cell immune response and clinical significance in stage III-IVa nasopharyngeal carcinoma (NPC), aiming to provide ideas and evidence for immunotherapy in NPC. Methods Fifty-nine NPC patients admitted to the Affiliated Tumor Hospital of Xinjiang Medical University from February 2018 to October 2020 for primary treatment were collected. Peripheral blood monocytes (PBMCs) were stimulated by LMP antigen. Intracellular cytokine staining and flow cytometry were applied to study the expression levels of IL-2, IL-13, interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) from CD4⁺T and CD8⁺ T cells, and then analyzed in conjunction with clinical factors. Results The positive rates of total PBMCs to LMP1 and LMP2 in NPC patients were different. The positive rate of LMP1 specific CD4⁺ T cells was statistically higher in stage T₃-T₄ NPC than that in stage T₁-T₂ (51.0% vs. 10.0%, P=0.042). There were also differences in the expression of cytokines between LMP1 and LMP2, CD4⁺T cells and CD8⁺T cells. Survival analysis showed the 2-year and 3-year overall survival (OS) rates were 91.5% and 88.2%, and the 2-year and 3-year progression-free survival (PFS) rates were 83.3% and 75.3%. Univariate analysis suggested that smoking history, male and LMP1 stimulated IL-13 positive expression in CD4⁺ T cells affected the disease progression (P=0.026, 0.045 and 0.006); multivariate analysis showed LMP1 stimulated IL-13 positive expression in CD4⁺ T cells and smoking history were the independent prognostic factors affecting PFS (P=0.017, 0.019). Conclusions LMP1 and LMP2 generate specific T-cell immune response in PBMCs of NPC patients, with differential expression in two T-cell subsets. LMP1 and LMP2 specific T cell immune response is associated with primary tumor size and metastatic lymph node volume. LMP1 stimulated IL-13 positive expression in CD4⁺ T cells and smoking history affects the disease progression.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Cui Haobo
	Chen Ting
	Fan Peiwen
	Wang Ruozheng

Key words： Nasopharyngeal carcinoma Epstein-Barr virus Latent membrane protein Specific T cell immune response Cultured intracellular cytokine staining

Received: 28 February 2022

Corresponding Authors: Wang Ruozheng, Email: wrz8526@vip.163.com

Cite this article:

Cui Haobo,Chen Ting,Fan Peiwen et al. Analysis of LMP specific T cell immune response and clinical factors in stage III-IVa nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2023, 32(2): 99-105.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20220228-00079 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2023/V32/I2/99

[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660.
[2] Lee AW, Ma BB, Ng WT, et al.Management of nasopharyngeal carcinoma: current practice and future perspective[J]. J Clin Oncol, 2015,33(29):3356-3364. DOI: 10.1200/JCO.2015.60.9347.
[3] 伍艳玲, 陈雨沛, 马骏. 局部晚期鼻咽癌放疗与化疗联合治疗进展[J].中华放射肿瘤学杂志,2021,30(10):1084-1088. DOI: 10.3760/cma.j.cn113030-20200215-00061.
Wu YL, Chen YP, Ma J.Research progress on radiotherapy combined with chemotherapy for locally advanced nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2021,30(10):1084-1088. DOI: 10.3760/cma.j.cn113030- 20200215-00061.
[4] 何美霖, 易俊林. 复发鼻咽癌治疗现状[J].中华放射肿瘤学杂志,2021,30(11):1202-1208. DOI: 10.3760/cma.j.cn113030-20200220-00065.
He ML, Yi JL.Current treatment of recurrent nasopharngeal carcinoma[J]. Chin J Radiat Oncol,2021,30(11):1202-1208. DOI: 10.3760/cma.j.cn113030- 20200220-00065.
[5] Ayee R, Ofori M, Wright E, et al.Epstein Barr virus associated lymphomas and epithelia cancers in humans[J]. J Cancer, 2020,11(7):1737-1750. DOI: 10.7150/jca.37282.
[6] Ma M, Feng Y, Fan P, et al.Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma[J]. Infect Agent Cancer, 2018,13:35. DOI: 10.1186/s13027-018-0206-5.
[7] Taylor GS, Jia H, Harrington K, et al.A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer[J]. Clin Cancer Res, 2014,20(19):5009-5022. DOI: 10.1158/1078-0432.CCR-14-1122-T.
[8] Bentz GL, Whitehurst CB, Pagano JS.Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9[J]. J Virol, 2011,85(19):10144-10153. DOI: 10.1128/JVI.05035-11.
[9] Liu Y, Gong P, Zhou N, et al.Insufficient PINX1 expression stimulates telomerase activation by direct inhibition of EBV LMP1-NF-κB axis during nasopharyngeal carcinoma development[J]. Biochem Biophys Res Commun, 2019,514(1):127-133. DOI: 10.1016/j.bbrc.2019.04.104.
[10] Cai TT, Ye SB, Liu YN, et al.LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma[J]. PLoS Pathog, 2017,13(7):e1006503. DOI: 10.1371/journal.ppat.1006503.
[11] 梁杰珍. EB病毒编码潜伏膜蛋白LMP2A通过EGFR/Ca²+/Calpain/ITGβ4路径促进鼻咽癌细胞转移[D]. 南宁:广西医科大学, 2017.
Liang JZ.Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via EGFR/CA²+/CALPAIN/ITGβ4 axis[D].Nanning: Guangxi Medical University, 2017.
[12] Cho SG, Kim N, Sohn HJ, et al.Long-term outcome of extranodal NK/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs[J]. Mol Ther, 2015,23(8):1401-1409. DOI: 10.1038/mt.2015.91.
[13] Lei L, Li J, Liu M, et al.CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal[J]. Cent Eur J Immunol, 2018,43(2):117-122. DOI: 10.5114/ceji.2018. 77379.
[14] Freer G, Rindi L.Intracellular cytokine detection by fluorescence-activated flow cytometry: basic principles and recent advances[J]. Methods, 2013,61(1):30-38. DOI: 10.1016/j.ymeth.2013.03.035.
[15] Yarza R, Bover M, Agulló-Ortuño MT, et al.Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer[J]. J Exp Clin Cancer Res, 2021,40(1):202. DOI: 10.1186/s13046-021-02010-9.
[16] Lin MC, Lin YC, Chen ST, et al.Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo[J]. BMC Cancer, 2017,17(1):18. DOI: 10.1186/s12885-016-3027-1.
[17] 郑之勤. SALL4、NYESO1、SSX2、LMP2A蛋白在鼻咽癌患者外周血中诱导的免疫反应研究[D]. 乌鲁木齐: 新疆医科大学, 2018.
Zheng ZQ.Immunoreaction study of SALL4, NYESO1, SSX2 and LMP2A protein in peripheral blood of patients with nasopharyngeal carcinoma [D]. Wulumuqi: Xinjiang Medical University, 2018.
[18] Salano VE, Mwakigonja AR, Abdulshakoor A, et al.Epstein-Barr virus latent membrane protein-1 expression in nasopharyngeal carcinoma[J]. JCO Glob Oncol, 2021,7:1406-1412. DOI: 10.1200/GO.21.00120.
[19] Sohn DH, Sohn HJ, Lee HJ, et al.Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs[J]. PLoS One, 2015,10(5):e0127899. DOI: 10.1371/journal.pone.0127899.
[20] Couture A, Garnier A, Docagne F, et al.HLA-class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy[J]. Front Immunol, 2019,10:1081. DOI: 10.3389/fimmu.2019.01081.
[21] Christofi T, Baritaki S, Falzone L, et al. Current perspectives in cancer immunotherapy[J]. Cancers (Basel), 2019,11(10)DOI: 10.3390/cancers11101472.
[22] Shastri MD, Allam V, Shukla SD, et al.Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases[J]. Life Sci, 2021,283:119871. DOI: 10.1016/j.lfs.2021.119871.
[23] Li X, Liu M, Shi Q, et al.Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma[J]. Hematol Oncol, 2022,DOI: 10.1002/hon.2993.